精神分裂症治疗相关靶点及药物研究进展
Receptors and Related Drug Development for Schizophrenia: Research Advances

作者: 贾晓凤 , 何 玲 :中国药科大学,江苏 南京;

关键词: 精神分裂症药物治疗靶点Schizophrenia Treatment Drugs Receptors

摘要:
精神分裂症是一种慢性致残性精神障碍。由于发病早、病程长、发病率高且病情严重,精神分裂症给社会带来沉重的经济负担。目前对精神分裂症的治疗主要使用典型和非典型抗精神分裂症药物。然而典型抗精神分裂症药物仅对阳性症状有效且同时还伴有严重的锥体外系不良反,非典型抗精神分裂症药物虽然对阴性症状和认知障碍有一定改善作用且锥体外系不良反发生率显著降低,但却又出现其他不良反应。因此,需要开发更为安全有效的抗精神分裂症药物。近年来研究发现,与抗精神分裂症药物开发相关的靶点包括多巴胺受体、5-HT受体、Glu受体、大麻受体和sigma受体等。本文对与精神分裂症相关的靶点及药物研究进展进行综述。

Abstract: Schizophrenia is a chronic disabling mental disorder. Because of its severity, chronicity, early age of onset, and prevalence, schizophrenia is the source of enormous human and economic costs. At present, schizophrenia is treated with typical and atypical antipsychotics. However, typical anti-psychotics are effective only in treating positive symptoms, and they may result in extrapyramidal side-effects. Although atypical antipsychotics have a certain improvement in negative symptoms and cognitive impairment and do not produce the extrapyramidal side-effects, there are other side effects. Therefore, we need more effective and safer antipsychotics. Recent studies found that those receptors associated with schizophrenia, such as dopamine receptor, 5-hydroxytryptamine receptor, glutamate receptor, cannabinoid receptor, sigma receptor and so on. This review summarizes the receptors and relevant drug development associated with Schizophrenia in recent years.

文章引用: 贾晓凤 , 何 玲 (2016) 精神分裂症治疗相关靶点及药物研究进展。 药物资讯, 5, 19-24. doi: 10.12677/PI.2016.52004

参考文献

[1] Insel, T.R. (2010) Rethinking Schizophrenia. Nature, 468, 187-193.
http://dx.doi.org/10.1038/nature09552

[2] 张立勇, 陈云芳. 抗精神病药对精神分裂症患者认知功能的影响[J]. 临床精神医学杂志, 2005, 15(1): 21-22.

[3] 汪开达. 精神药理学[M]. 北京: 人民卫生出版社, 2007.

[4] Brunetti, M., Tizio, L.D., Dezi, S., et al. (2012) Aripiprazole, Alcohol and Substance Abuse: A Review. European Review for Medical & Pharmacological Sciences, 16, 1346-1354.

[5] Henderson, D.C., Fan, X.D., Copeland, P.M., et al. (2009) Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizo-phrenia Patients. Journal of Clinical Psychopharmacology, 29, 165-169.
http://dx.doi.org/10.1097/JCP.0b013e31819a8dbe

[6] 罗毅, 诸秉根, 杜洁. 利培酮与阿立哌唑治疗精神分裂症的疗效与安全性对比[J]. 现代仪器与医疗, 2015(6): 110-112.

[7] 马帅, 温颖玲, 周伟澄. 2015年美国FDA批准上市的新药简介[J]. 中国医药工业杂志, 2016, 47(1): 79-105.

[8] Gyertyán, I., Kiss, B., Sághy, K., et al. (2011) Cariprazine (RGH-188), a Potent D3/D2 Dopamine Receptor Partial Agonist, Binds to Dopamine D3 Receptors in Vivo and Shows An-tipsychotic-Like and Procognitive Effects in Rodents. Neurochemistry International, 59, 925-935.
http://dx.doi.org/10.1016/j.neuint.2011.07.002

[9] 赵爱玲, 赵靖平. 多巴胺和5-羟色胺受体基因多态性与抗精神病药反应[J]. 国外医学: 精神病学分册, 2002(2): 101-104.

[10] Sumiyoshi, T., Matsui, M., Nohara, S., et al. (2001) En-hancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment. American Journal of Psychiatry, 158, 1722-1725.
http://dx.doi.org/10.1176/appi.ajp.158.10.1722

[11] Marek, G. and Merchant, K. (2005) Developing Therapeutics for Schizophrenia and Other Psychotic Disorders. Neurorx, 2, 579-589.
http://dx.doi.org/10.1602/neurorx.2.4.579

[12] Woods, S., Clarke, N.N., Layfield, R. and Fone, K.C.F. (2012) 5-HT6 Receptor Agonists and Antagonists Enhance Learning and Memory in a Conditioned Emotion Response Paradigm by Mod-ulation of Cholinergic and Glutamatergic Mechanisms. British Journal of Pharmacology, 167, 436-449.
http://dx.doi.org/10.1111/j.1476-5381.2012.02022.x

[13] Dall’Olio, R. and Gandolfi, O. (1993) The NMDA Positive Modulator D-Cycloserine Potentiates the Neuroleptic Activity of D1 and D2 Dopamine Receptor Blockers in the Rat. Psy-chopharmacology, 110, 165-168.
http://dx.doi.org/10.1007/BF02246967

[14] Goff, D.C., Tsai, G., Manoach, D.S. and Coyle, JT. (1995) Dose-Finding Trial of D-Cycloserine Added to Neuroleptics for Negative Symptoms in Schizophrenia. The American Journal of Psychiatry, 152, 1213-1215.
http://dx.doi.org/10.1176/ajp.152.8.1213

[15] Mezler, M., Geneste, H.L. and Marek, G.J. (2010) LY-2140023, a Pro-drug of the Group II Metabotropic Glutamate Receptor Agonist LY-404039 for the Potential Treatment of Schizophrenia. Current Opinion in Investigational Drugs, 11, 833-845.

[16] Kinon, B.J., Lu, Z., Millen, B.A., et al. (2011) A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients with DSM-IV Schizophrenia. Journal of Clinical Psychopharmacology, 31, 349-355.
http://dx.doi.org/10.1097/JCP.0b013e318218dcd5

[17] Fulmer, T. (2008) Schizophrenia Develops a Complex. Sci-ence-Business eXchange, 1, 5-6.
http://dx.doi.org/10.1038/scibx.2008.129

[18] Mechoulam, R. and Parker, L.A. (2013) The Endocannabinoid System and the Brain. Annual Review of Psychology, 64, 21-47.
http://dx.doi.org/10.1146/annurev-psych-113011-143739

[19] Hillard, C.J., Weinlander, K.M. and Stuhr, K.L. (2011) Contributions of Endocannabinoid Signaling to Psychiatric Disorders in Humans: Genetic and Biochemical Evidence. Neu-roscience, 204, 207-229.
http://dx.doi.org/10.1016/j.neuroscience.2011.11.020

[20] Sewell, R.A., Ranganathan, M. and D’Souza, D.C. (2009) Cannabinoids and Psychosis. International Review of Neurobiology, 21, 152-162.
http://dx.doi.org/10.1080/09540260902782802

[21] Marco, E.M., García-Gutiérrez, M.S., Bermúdez-Silva, F.J., Moreira, F.A., Guimarães, F., Manzanares, J. and Viveros, M.-P. (2011) Endocannabinoid System and Psychiatry: In Search of a Neurobiological Basis for Detrimental and Potential Therapeutic Effects. Frontiers in Behavioral Neuroscience, 5, 63.
http://dx.doi.org/10.3389/fnbeh.2011.00063

[22] Zavitsanou, K. and Dalton, V.S. (2011) Paranoid Schizophrenia Is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex. Neuropsychopharmacology, 36, 1620-1630.
http://dx.doi.org/10.1038/npp.2011.43

[23] Coulston, C.M., Perdices, M., Henderson, A.F. and Malhi, G.S. (2011) Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use. Schizophrenia Research & Treatment, 2011, Article ID: 50172.

[24] Roser, P., Vollenweider, F.X. and Kawohl, W. (2010) Potential Antipsychotic Properties of Central Cannabinoid (CB1) Receptor Antagonists. The World Journal of Biological Psychiatry, 11, 208-219.
http://dx.doi.org/10.3109/15622970801908047

[25] Zamberletti, E., Viganò, D., Guidali, C., Rubino, T. and Parolaro, D. (2010) Long-Lasting Recovery of Psychotic-Like Symptoms in Isolation-Reared Rats after Chronic but Not Acute Treatment with the Cannabinoid Antagonist AM251. International Journal of Neuropsychopharmacology, 15, 267-280.
http://dx.doi.org/10.1017/S1461145710001185

[26] Black, M.D., Stevens, R.J., Rogacki, N., et al. (2010) AVE1625, a Cannabinoid CB1 Receptor Antagonist, as a Co-Treatment with Antipsychotics for Schizophrenia: Improvement in Cognitive Function and Reduction of Antipsychotic-Side Effects in Rodents. Psychopharmacology, 215, 149-163.
http://dx.doi.org/10.1007/s00213-010-2124-0

[27] Maurice, T. and Su, T.-P. (2009) The Pharmacology of Sigma-1 Receptors. Pharmacology & Therapeutics, 124, 195- 206.
http://dx.doi.org/10.1016/j.pharmthera.2009.07.001

[28] Paschos, K.A., Stavroula, V. and Ekaterini, C. (2009) Neuro-peptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression. CNS Drugs, 23, 755-772.
http://dx.doi.org/10.2165/11310830-000000000-00000

[29] Ishima, T., Fujita, Y., Kohno, M., et al. (2009) Improvement of Phencyclidine Induced Cognitive Deficits in Mice by Subsequent Subchronic Administration of Fluvoxamine, but Not Sertraline. The Open Clinical Chemistry Journal, 2, 7-11.
http://dx.doi.org/10.2174/1874241600902010007

[30] Kunitachi, S., Fujita, Y., Ishima, T., Kohno, M., Horio, M., Tanibuchi, Y., Shirayama, Y., Iyo, M. and Hashimoto, K. (2014) Phencyclidine-Induced Cognitive Deficits in Mice Are Ameliorated by Subsequent Subchronic Administration of Donepezil: Role of Sigma-1 Receptors. Brain Research, 1279, 189-196.

[31] Tomihisa, N., Masaomi, I. and Kenji, H. (2012) Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases. Current Pharmaceutical Design, 18, 875-883.
http://dx.doi.org/10.2174/138161212799436476

分享
Top